Condition: Choroidal Neovascularization · Mineralocorticoid Excess · Sponsor: Institut National de la Santé Et de la Recherche Médicale, France
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
This description comes directly from the study's public registry record.
Francine Behar-Cohen, Dr · 01 44 27 81 64 · francine.cohen@aphp.fr
Always discuss trial participation with your own doctor first.
| Ophtalmopole Hôpital Cochin | Paris, France | Recruiting |
| Hôpital Foch | Suresnes, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04439708